# US 2006/0040897 A1 · Compositions for treating and/or preventing diseases characterized by the presence of metal ions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0040897 A1
- Document ID: US20060040897A1
- Status: Published application
- Kind: A1
- Application number: 11/132,170
- Filed: 2005-05-17
- Published: 2006-02-23
- Earliest claimed: 2002-11-18
- Assignees: GrenPharma LLC
- Inventors: Orrie Friedman; Ivan Correia; Toby Sommer; David Kew
- Web page: https://patentgrep.com/patent/US20060040897A1

## CPC

- A61K 31/695: Silicon compounds
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention generally relates to the treatment and/or prevention of Alzheimer's disease, other neurodegenerative diseases, and/or diseases characterized by the presence of certain metal ions, by using certain compositions including organosilicon compounds. A composition of the invention may be administered to a mammal, such as a human. In some cases, the composition may include a silanol, a silandiol, a silantriol, or a cyclic organosilane, and/or be able to form a silanol, a silandiol, or a silantriol upon exposure to physiological conditions such as are found in the blood, in the stomach and/or gastrointestinal tract, or in the brain or other organ. In certain cases, the organosilicon compound may be bound to a moiety able to be transported across the blood-brain barrier into the brain, for example, an amino acid, a peptide, a protein, a virus, etc. The organosilicon compound may also be labeled (e.g., fluorescently or radioactively) in certain instances. In some embodiments, the composition, or a portion thereof, may sequester aluminum, copper, iron or other ions, for example, by electrostatically binding to the ions. The composition may also include other functionalities such as amines, certain alkyl and/or aryl moieties (including substituted alkyls and/or aryls), or hydrophobic moieties, for example, to facilitate transport of the organosilicon compound through the blood-brain barrier.

## Claims

### Claim 1

A method of treating or preventing Alzheimer's disease or other neurological disorder, comprising:
administering, to a subject, a therapeutically effective amount of a composition comprising a compound having a structure:
wherein:
each of Z1, Z2, Z3, and Z4 independently is one of H, X, R, OH, OR1, or NJ1J2,
R comprising at least one carbon atom,
X being a halogen,
R1 comprising at least one carbon atom, and
J1 and J2 each independently being H, or comprising at least one of a carbon atom, a nitrogen atom, an oxygen atom, or a sulfur atom;
and wherein:
at least one of Z1, Z2, Z3, and Z4 comprises at least one carbon atom;
Z1, Z2, Z3, and Z4 are not all, simultaneously, one of H or R; and
Z1, Z2, Z3, and Z4 are not all simultaneously acetate;
or a salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is not otherwise indicated for treatment with the composition.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition is not able to cross the blood-brain barrier of the subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition is able to cross the blood-brain barrier of the subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein at least one of Z1, Z2, Z3, and Z4 independently is X.

### Claim 6 (depends on 5)

The method of claim 5, wherein at least two of Z1, Z2, Z3, and Z4 independently are X.

### Claim 7

(canceled)

### Claim 8 (depends on 5)

The method of claim 5, wherein at least one of Z1, Z2, Z3, and Z4 is Cl.

### Claim 9 (depends on 8)

The method of claim 8, wherein at least two of Z1, Z2, Z3, and Z4 is Cl.

### Claim at position 10

10-33. (canceled)

### Claim 34 (depends on 1)

The method of claim 1, wherein at least one of Z1, Z2, Z3, and Z4 comprises a carbon atom covalently bonded to Si.

### Claim 35 (depends on 34)

The method of claim 34, wherein at least one of Z1, Z2, Z3, and Z4 independently is R.

### Claim 36 (depends on 35)

The method of claim 35, wherein at least two of Z1, Z2, Z3, and Z4 independently are R.

### Claim 37

(canceled)

### Claim 38 (depends on 35)

The method of claim 35, wherein at least one R is an alkyl.

### Claim 39 (depends on 38)

The method of claim 38, wherein at least one alkyl is methyl.

### Claim 40 (depends on 38)

The method of claim 38, wherein at least one alkyl is ethyl.

### Claim 41 (depends on 38)

The method of claim 38, wherein at least one alkyl is isopropyl.

### Claim at position 19

42-52. (canceled)

### Claim 53 (depends on 1)

The method of claim 1, wherein at least one of Z1, Z2, Z3, and Z4 comprises a silicon atom.

### Claim at position 21

54-89. (canceled)

### Claim 90 (depends on 1)

The method of claim 1, wherein the compound has a structure:

### Claim 91 (depends on 1)

The method of claim 1, wherein administrating comprises administrating the composition into the brain of the subject.

### Claim at position 24

92-148. (canceled)

### Claim 149

A method of treating or preventing Alzheimer's disease or other neurological disorder, comprising:
administering, to a subject, a therapeutically effective amount of a composition comprising a compound comprising, within the molecular structure of the compound, at least two silicon atoms.

### Claim at position 26

150-157. (canceled)

### Claim 158

A composition, comprising:
a compound having a structure:
wherein:
each of Z1, Z2, Z3, and Z4 independently is one of H, X, R, OH, OR1, or NJ1J2,
R comprising at least one carbon atom,
X being a halogen,
R1 comprising at least one carbon atom, and
J1 and J2 each independently being H, or comprising at least one of a carbon atom, a nitrogen atom, an oxygen atom, or a sulfur atom;
and wherein:
at least one of Z1, Z2, Z3, and Z4 comprises at least one carbon atom;
Z1, Z2, Z1, and Z4 are not all, simultaneously, one of H or R; and
Z1, Z2, Z3, and Z4 are not all simultaneously acetate;
or a salt thereof;
in combination with a pharmaceutically acceptable carrier.

### Claim at position 28

159-181. (canceled)
